

Hepatic Cirrhosis Market - A Global and Regional Analysis: Focus on Disease Type, Treatment, Country, and Region - Analysis and Forecast, 2026-2036

<https://marketpublishers.com/r/H8C802F5B33AEN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: H8C802F5B33AEN

Abstracts

The global hepatic cirrhosis market is experiencing notable growth, driven by increasing cases of liver diseases, advancements in treatment options, and improving healthcare infrastructure worldwide. Hepatic cirrhosis, a condition where the liver becomes severely scarred, is predominantly caused by chronic liver diseases such as hepatitis, alcohol abuse, and non-alcoholic fatty liver disease (NAFLD), now commonly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD). These conditions are becoming more prevalent globally, leading to a rise in cirrhosis cases, particularly among older populations and in regions where lifestyle factors such as excessive alcohol consumption and poor dietary habits are widespread.

The market is witnessing a surge in innovative therapies, including antiviral drugs for hepatitis-induced cirrhosis, immunosuppressants for autoimmune-related cirrhosis, and antifibrotic agents aimed at reducing liver fibrosis. These treatments are providing new hope for patients, especially with liver transplantation becoming a critical option for those with end-stage cirrhosis. However, despite the growth opportunities, challenges remain, particularly in terms of high treatment costs and limited awareness of liver diseases in some regions, which often leads to late diagnoses and delayed treatments. Additionally, the healthcare infrastructure in many low-resource regions is inadequate to support the growing demand for cirrhosis treatment.

North American market remains the largest due to its advanced healthcare infrastructure, high awareness of liver diseases, and extensive treatment options. Europe follows with steady growth, driven by increasing investments in healthcare and advancements in research. However, the Asia-Pacific region is expected to witness the highest growth rate, primarily due to improving healthcare access, rising disease

awareness, and a growing patient population in countries like China and India. Latin America and the Middle East & Africa are also emerging markets, with increasing access to healthcare services and a greater focus on addressing liver disease burden.

Furthermore, emerging markets in Asia-Pacific, Latin America, and the Middle East present significant growth potential due to improvements in healthcare access, rising disease awareness, and expanding medical technologies. The increasing focus on personalized medicine—tailoring treatments based on individual genetic profiles presents another promising avenue for more effective management of hepatic cirrhosis. Key players in the market, such as Gilead Sciences, Novartis, Bristol-Myers Squibb, and GSK, are leading the charge in research and development, with new therapies aiming to address unmet needs in cirrhosis care. These companies are leveraging strategic collaborations and acquisitions, such as GSK's recent acquisition of Boston Pharmaceuticals for \$2 billion to gain access to efimosfermin, an innovative liver disease drug.

The hepatic cirrhosis market is highly competitive, with several key players leading the charge in treatment development. Companies such as Gilead Sciences, Novartis, and Bristol-Myers Squibb are at the forefront, developing antiviral drugs, antifibrotic agents, and other therapeutics. Smaller, innovative companies like Akeru Therapeutics and Intercept Pharmaceuticals are also making significant strides with new drug candidates targeting non-alcoholic steatohepatitis (NASH) and liver fibrosis. Strategic partnerships and acquisitions are common in this space as companies work to expand their portfolios and access emerging markets. For example, Novo Nordisk recently acquired Akeru Therapeutics to strengthen its position in the liver disease market

In conclusion, the hepatic cirrhosis market is poised for continued expansion, with significant advancements in treatment options, ongoing research, and a rising global burden of liver diseases. The market's future will be shaped by innovations in medical therapies, increasing healthcare access, and enhanced public awareness to address the growing prevalence of this chronic liver condition.

Market Segmentation:

Segmentation 1: by Disease Type

Alcoholic Cirrhosis

Atrophic Cirrhosis

Biliary Cirrhosis

Cryptogenic Cirrhosis

Segmentation 2: by Treatment

Antiviral Drugs

Immunosuppressants

Corticosteroids

Liver Transplantation

Antifibrotic Agents

Segmentation 3: by Region

North America

Europe

Asia-Pacific

Rest-of-the-World

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days.

Contents

Executive Summary

Scope of Study

1. GLOBAL HEPATIC CIRRHOSIS MARKET: INDUSTRY OUTLOOK

1.1 Market Overview and Ecosystem

1.2 Overview of Global Hepatic Cirrhosis Disease

1.3 Epidemiological Analysis of Hepatic Cirrhosis Market

1.3.1 Etiology

1.3.2 Risk factors

1.3.3 Demographic Analysis

1.3.4 Pathophysiology of Disease

1.4 Diagnosis of Hepatic Cirrhosis

1.4.1 Diagnostic Algorithm

1.4.2 Diagnostic Guidelines

1.5 Market Trends

1.6 Regulatory Landscape Analysis

1.6.1 Legal Requirement and Framework in U.S.

1.6.2 Legal Requirement and Framework in E.U.

1.6.3 Legal Requirement and Framework in Asia-Pacific

1.6.4 Legal Requirement and Framework in Rest-of-the-World

1.7 Market Dynamics

1.7.1 Impact Analysis

1.7.2 Market Drivers

1.7.3 Market Restraints

1.7.4 Market Opportunities

2. GLOBAL HEPATIC CIRRHOSIS MARKET, (BY DISEASE TYPE), \$MILLION, 2025-2036

2.1 Overview

2.2 Alcoholic Cirrhosis

2.3 Atrophic Cirrhosis

2.4 Biliary Cirrhosis

2.5 Cryptogenic Cirrhosis

3. GLOBAL HEPATIC CIRRHOSIS MARKET, (BY TREATMENT), \$MILLION,

2025-2036

- 3.1 Overview
- 3.2 Antiviral Drugs
- 3.3 Immunosuppressants
- 3.4 Corticosteroids
- 3.5 Liver Transplantation
- 3.6 Antifibrotic Agents

4. GLOBAL HEPATIC CIRRHOSIS MARKET, (BY REGION), \$MILLION, 2025-2036

- 4.1 North America
 - 4.1.1 Key Findings
 - 4.1.2 Market Dynamics
 - 4.1.3 Market Sizing and Forecast
 - 4.1.3.1 North America Hepatic Cirrhosis Market (by Country)
 - 4.1.3.1.1 U.S.
 - 4.1.3.1.2 Canada
- 4.2 Europe
 - 4.2.1 Key Findings
 - 4.2.2 Market Dynamics
 - 4.2.3 Market Sizing and Forecast
 - 4.2.3.1 Europe Hepatic Cirrhosis Market (by Country)
 - 4.2.3.1.1 Germany
 - 4.2.3.1.2 France
 - 4.2.3.1.3 Italy
 - 4.2.3.1.4 Spain
 - 4.2.3.1.5 U.K.
 - 4.2.3.1.6 Rest-of-Europe
- 4.3 Asia-Pacific
 - 4.3.1 Key Findings
 - 4.3.2 Market Dynamics
 - 4.3.3 Market Sizing and Forecast
 - 4.3.3.1 Asia-Pacific Hepatic Cirrhosis Market (by Country)
 - 4.3.3.1.1 Japan
 - 4.3.3.1.2 China
 - 4.3.3.1.3 Rest-of-Asia-Pacific
- 4.4 Rest-of-the-World
 - 4.4.1 Key Findings

- 4.4.2 Market Dynamics
- 4.4.3 Market Sizing and Forecast

5. GLOBAL HEPATIC CIRRHOSIS MARKET: COMPETITIVE BENCHMARKING AND COMPANY PROFILES

- 5.1 Competitive Benchmarking
- 5.2 Competitive Landscape
 - 5.2.1 Key Strategies and Developments by Company
 - 5.2.1.1 Funding Activities
 - 5.2.1.2 Mergers and Acquisitions
 - 5.2.1.3 Regulatory Approvals
 - 5.2.1.4 Partnerships, Collaborations, and Business Expansions
 - 5.2.2 Key Developments Analysis
- 5.3 Company Profiles
 - 5.3.1 Abbott
 - 5.3.1.1 Company Overview
 - 5.3.1.2 Product Portfolio
 - 5.3.1.3 Target Customers/End Users
 - 5.3.1.4 Key Personnel
 - 5.3.1.5 Analyst View
 - 5.3.2 Astellas Pharma, Inc.
 - 5.3.2.1 Company Overview
 - 5.3.2.2 Product Portfolio
 - 5.3.2.3 Target Customers/End Users
 - 5.3.2.4 Key Personnel
 - 5.3.2.5 Analyst View
 - 5.3.3 Gilead Sciences, Inc.
 - 5.3.3.1 Company Overview
 - 5.3.3.2 Product Portfolio
 - 5.3.3.3 Target Customers/End Users
 - 5.3.3.4 Key Personnel
 - 5.3.3.5 Analyst View
 - 5.3.4 Novartis AG
 - 5.3.4.1 Company Overview
 - 5.3.4.2 Product Portfolio
 - 5.3.4.3 Target Customers/End Users
 - 5.3.4.4 Key Personnel
 - 5.3.4.5 Analyst View

5.3.5 Takeda Pharmaceuticals

5.3.5.1 Company Overview

5.3.5.2 Product Portfolio

5.3.5.3 Target Customers/End Users

5.3.5.4 Key Personnel

5.3.5.5 Analyst View

5.3.6 Grifols Therapeutics Inc.

5.3.6.1 Company Overview

5.3.6.2 Product Portfolio

5.3.6.3 Target Customers/End Users

5.3.6.4 Key Personnel

5.3.6.5 Analyst View

5.3.7 Cellaion

5.3.7.1 Company Overview

5.3.7.2 Product Portfolio

5.3.7.3 Target Customers/End Users

5.3.7.4 Key Personnel

5.3.7.5 Analyst View

6. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Hepatic Cirrhosis Market (by Scenario), \$Million, 2025, 2030, and 2036

Figure: Global Hepatic Cirrhosis Market, 2025 and 2036

Figure: Global Hepatic Cirrhosis Market Key Trends, Impact Analysis

Figure: North America Hepatic Cirrhosis Market, \$Million, 2025-2036

Figure: Europe Hepatic Cirrhosis Market, \$Million, 2025-2036

Figure: Asia-Pacific Hepatic Cirrhosis Market, \$Million, 2025-2036

Figure: Rest-of-the-World Hepatic Cirrhosis Market, \$Million, 2025-2036

List Of Tables

LIST OF TABLES

Table: Market Snapshot

Table: Market Dynamics

Table: Global Hepatic Cirrhosis Market (by Disease Type), \$Million, 2025-2036

Table: Global Hepatic Cirrhosis Market (by Treatment), \$Million, 2025-2036

Table: Global Hepatic Cirrhosis Market (by Region), \$Million, 2025-2036

I would like to order

Product name: Hepatic Cirrhosis Market - A Global and Regional Analysis: Focus on Disease Type, Treatment, Country, and Region - Analysis and Forecast, 2026-2036

Product link: <https://marketpublishers.com/r/H8C802F5B33AEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H8C802F5B33AEN.html>